Cubist Pharms Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUBIST PHARMS LLC
CUBIST PHARMS LLC has six approved drugs.
There are twenty-six US patents protecting CUBIST PHARMS LLC drugs.
Drugs and US Patents for Cubist Pharms Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | 11,278,622*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cubist Pharms Llc | DIFICID | fidaxomicin | TABLET;ORAL | 201699-001 | May 27, 2011 | AB | RX | Yes | Yes | 7,863,249*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | 9,624,250 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Cubist Pharms Llc | DIFICID | fidaxomicin | TABLET;ORAL | 201699-001 | May 27, 2011 | AB | RX | Yes | Yes | 7,906,489*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | 7,129,232*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cubist Pharms Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 8,058,238 | ⤷ Start Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | RE39071 | ⤷ Start Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 5,912,226 | ⤷ Start Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 8,129,342 | ⤷ Start Trial |
| Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | RE39071 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST PHARMS LLC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
| ➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
International Patents for Cubist Pharms Llc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Tunisia | 2011000381 | ⤷ Start Trial |
| Mexico | 348083 | ⤷ Start Trial |
| Spain | 2290498 | ⤷ Start Trial |
| Serbia | 58119 | ⤷ Start Trial |
| Mexico | 373309 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cubist Pharms Llc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1556389 | 122015000113 | Germany | ⤷ Start Trial | PRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918 |
| 1699784 | 1590047-5 | Sweden | ⤷ Start Trial | PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/991 20150325 |
| 1539977 | SPC/GB15/020 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: FIDAXOMICIN; REGISTERED: UK EU/1/11/733/001 20111207; UK EU/1/11/733/002 20111207; UK EU/1/11/733/003 20111207; UK EU/1/11/733/004 20111207 |
| 1539977 | 15C0028 | France | ⤷ Start Trial | PRODUCT NAME: FIDAXOMICINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/733/001-004 20111207 |
| 1699784 | PA2015032,C1699784 | Lithuania | ⤷ Start Trial | PRODUCT NAME: TEDIZOLIDAS, PASIRINKTINAI ESTERIO PAVIDALU, YPAC FOSFATO ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/991 20150323 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

